Rolf Günther to steer Bicycle Therapeutics
This article was originally published in Scrip
Executive Summary
Bicycle Therapeutics, the Cambridge, UK-based biotech firm that is developing a bicyclic peptide technology for the discovery of a new class of drug candidates with antibody-like selectivity and specificity but the potential for manufacturing at a similar cost to new chemical entities, has appointed Dr Rolf Günther as CEO. Previously, Dr Günther was CEO and COO of Affimed, where he will continue to serve as COO in a part-time role until August. Bicycle Therapeutics’ technology is based on discoveries made by its founders, Professor Christian Heinis and Sir Gregory Winter, at the MRC Laboratory of Molecular Biology in Cambridge.